quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:50:00·45d
PRRelease
AtaiBeckley Inc. logo
COMPASS Pathways Plc logo
Definium Therapeutics Inc. logo
+2

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

ATAI· AtaiBeckley Inc.CMPS· COMPASS Pathways PlcDFTX· Definium Therapeutics Inc.GHRS· GH Research PLCHELP· Cybin Inc.
Health Care
Original source

Companies

  • ATAI
    AtaiBeckley Inc.
    Health Care
  • CMPS
    COMPASS Pathways Plc
    Health Care
  • DFTX
    Definium Therapeutics Inc.
    Health Care
  • GHRS
    GH Research PLC
    Health Care
  • HELP
    Cybin Inc.
    Health Care

Recent analyst ratings

  • Apr 17DFTXUpdateStifel$30.00
  • Apr 13HELPUpdateTD Cowen$8.00
  • Apr 10DFTXUpdatePiper Sandler$49.00
  • Mar 27ATAIUpdateDeutsche Bank$12.00
  • Feb 24DFTXUpdateWolfe Research$25.00
  • Feb 2HELPUpdateJefferies$22.00

Related

  • SEC14h
    SEC Form 6-K filed by Cybin Inc.
  • PR1d
    Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
  • INSIDER1d
    SEC Form 4 filed by Craig Kevin James
  • SEC1d
    Amendment: SEC Form SCHEDULE 13G/A filed by Cybin Inc.
  • SEC1d
    SEC Form DEFA14A filed by AtaiBeckley Inc.
  • SEC1d
    SEC Form DEF 14A filed by AtaiBeckley Inc.
  • SEC1d
    Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR1d
    Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022